Recent developments include strategic partnerships and financing agreements to expand wellness and stem cell therapy services, alongside regulatory challenges related to Nasdaq listing.

• EUDA Health and Guangdong Cell Biotech are exploring a strategic partnership to enhance wellness and biotech service offerings [N1].
• The company received a Nasdaq delisting warning due to its market capitalization falling below required levels [N2].
• EUDA entered into a convertible loan agreement with Shenzhen Inno to further expand its stem cell therapy platform [N3].
• The company has been part of broader biotech sector momentum with peer companies rallying on trial data and earnings updates [N4][N5][N6][N7].

EUDA's strategic partnerships, such as the convertible loan agreement with Shenzhen Inno and exploration of collaboration with Guangdong Cell Biotech, indicate efforts to expand its stem cell therapy platform and wellness services. The company's focus on property management combined with holistic wellness offerings could create diversified revenue streams. Management's experience and ongoing remediation of internal control weaknesses may improve operational effectiveness and investor confidence [N3][N1][S1].

The company has experienced recurring losses and a significant working capital deficit, with liquidity ratios indicating limited short-term financial flexibility. EUDA faces a Nasdaq delisting warning due to its market capitalization falling below required thresholds. Material weaknesses in internal controls over financial reporting remain a concern, and the success of remediation efforts is uncertain. These factors, combined with the challenges of transitioning business focus and reliance on external financing, present risks to the company's financial stability and operational continuity [N2][S1].

EUDA's moat is supported by its experienced management team with deep knowledge in property management and wellness sectors, enabling it to address industry-specific client needs effectively. The company's expansion into stem cell therapy and holistic wellness services through partnerships and convertible loan agreements may enhance its service offerings. However, the company faces challenges including recurring operating losses, liquidity constraints, and internal control weaknesses, which may impact its competitive positioning [S1][N3][N1].

• Liquidity Risk: The company has a working capital deficit and low liquidity ratios, indicating potential challenges in meeting short-term obligations and funding operations.
• Nasdaq Delisting Risk: EUDA has received a Nasdaq delisting warning due to its market capitalization falling below required levels, which could impact its listing status and investor perception.
• Operational Risk: Material weaknesses in internal control over financial reporting have been identified, which may affect the accuracy and reliability of financial statements until remediated.
• Business Transition Risk: The strategic shift away from certain medical-related business units to focus on property management and wellness services involves execution risks and potential short-term disruptions.

• EUDA Health Holdings Ltd is a foreign private issuer listed on Nasdaq [S1].
• The company operates primarily in property management services and holistic wellness consumer products and services, including bioenergy cabin therapy packages and stem cell therapy services delivered through third-party treatment providers [S1].
• In 2025, revenue was approximately $6.82 million, with a net loss of about $2.7 million and basic and diluted EPS of -1.48 USD per share for the fiscal year ended December 31, 2025 [S1].
• The company had cash and cash equivalents of approximately $376,206 as of June 30, 2024, and current assets of about $1.04 million against current liabilities of approximately $5.84 million as of December 31, 2025, resulting in a current ratio of 0.18 and a cash ratio of 0.06 [S1].
• EUDA has experienced recurring operating losses since 2020 and had a working capital deficit of approximately $4.8 million as of December 31, 2025 [S1].
• The company has a material weakness in internal control over financial reporting related to account reconciliations and is undertaking remediation efforts including hiring qualified staff and consultants [S1].
• EUDA entered into a convertible loan agreement with Shenzhen Inno to expand its stem cell therapy platform [N3].
• The company is exploring a strategic partnership with Guangdong Cell Biotech [N1].
• EUDA Health has received a Nasdaq delisting warning due to its market capitalization falling below required levels [N2].
• The company has streamlined certain medical-related business units as a strategic shift, focusing more on property management and wellness services [S1].
• EUDA's management team has extensive experience in property management and wellness sectors, which supports its service delivery [S1].
• The company has no off-balance-sheet arrangements affecting liquidity or capital resources [S1].
• EUDA has adopted cybersecurity and insider trading policies to manage risks and comply with regulations [S1].